• Mechanism of Action
• Inhibits the Bcr-Abl tyrosine kinase as well as the stem cell receptor factor (cKIT) and several other receptor tyrosine kinases.

Clinical Use

• • Indications
  • First line treatment for chronic myeloid leukaemia
  • Philadelphia chromosome positive acute lymphoblastic leukaemia
  • Hypereosinophilic syndrome
  • cKIT positive unresectable or metastatic gastrointestinal stromal tumours
• • Adverse Effects
  • Rash
  • Fatigue
  • Oedema
  • Nausea / vomiting / diarrhoea
  • Muscle cramping
  • Peripheral neuropathy
  • LFT derangement
  • Myelosuppression - anaemia, neutropaenia, thrombocytopaenia